Edwards Lifesciences (EW) Stock Price & Analysis

EW$101.85-2.03 -1.95%
Medical - DevicesLarge CapHigh Quality
Compare
Market cap$58.56BEnterprise value$56.16BRevenue (TTM)$6.67BMarket positionTop 25%

Score

47
Neutral
Value
21
Quality
76
Growth
44

AI Analysis

Snapshot

Edwards Lifesciences scores 47/100, but the multiple is asking a lot (P/E 56.1, rich vs its own history). Under the hood: P/E 56.1, rich vs its own history, plus revenue compounding ~4% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

21
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

44
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

76
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Edwards Lifesciences Corporation (EW) last printed $101.85. Equity value is $58.56B. Trailing earnings multiple 58.49. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$2.96B$3.44B$3.72B$4.35B$4.39B$5.23B$5.38B$5.01B$5.44B$6.07B

About

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Edwards Lifesciences (EW) Stock Price & Analysis

EW price $101.85 -2.03 -1.95%

Ticker
EW
Price
$101.85
Change
-2.03 -1.95%
Market cap
$58.56B
P/E
58.49
Forward P/E
31.93
Dividend yield
0.00%
Beta
0.83
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
47
Value
21
Quality
76
Growth
44

Stocklytics score rationale: value 21, quality 76, growth 44.

AI Score 70. Edwards Lifesciences Corporation has a strong market cap of $57.3 billion and impressive gross profit margins of approximately 78.1%. However, its high price-to-earnings ratio of 56.1 and negative price-to-earnings growth ratio indicate potential overvaluation, which may limit future growth prospects

Insights · Forecast · Financials · Learn

Stocklytics home · Screener